The Ministry of Health, Labor and Welfare (MHLW) appears to be ready to begin post-launch drug price adjustments based on cost-effectiveness assessments (CEAs) for the first time since the system was introduced in April 2019. As price tweaks will be…
Gilead’s JAK Med Hits Shelves in Japan; Launch Being Prepped for Oral Semaglutide, Rakuten Photoimmunotherapy
To read the full story
BUSINESS
- Meiji to Discontinue Sale of Kobayashi Kako Products after Biz Suspension
February 26, 2021
- Mylan EPD Offering EpiPen for Free to Prep for Possible Vaccine Reactions
February 26, 2021
- Daiichi Sankyo, France/Belgium Lymphoma Group to Collaborate on Valemetostat Trial
February 26, 2021
- MSD’s 9-Valent HPV Vaccine Now Available in Japan
February 25, 2021
- Ken Takeshita to Become Daiichi Sankyo’s Global R&D Head in April
February 25, 2021
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
By managing personal bias during the interview process, hiring managers can significantly improve their hit rate placing winning candidates. The trouble is, it’s easier said than done. It’s only natural we tend to like people we can relate to, people…